Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
08/10/2026 11:45
BRIEF-Biohaven Enters Strategic Licensing Agreement With Ono Pharma Oct 8 (Reuters) - ONO PHARMACEUTICAL CO., LTD. 4528.T:
BIOHAVEN ENTERS STRATEGIC LICENSING AGREEMENT WITH ONO PHARMA FOR EXTRACELLULAR IGG DEGRADERS IN JAPAN AND SELECT ASIAN REGIONS, LEAD CANDIDATE BHV-1300 IN PHASE 3 FOR GRAVES' DISEASE
BIOHAVEN - TO RECEIVE UP TO $100 MILLION PAYMENTS AND 20% ROYALTIES FROM ONO
BIOHAVEN - ONO OBTAINS EXCLUSIVE LICENSE FOR BIOHAVEN'S IGG DEGRADERS IN JAPAN, SOUTH KOREA, TAIWAN, ASEAN
Source text: ID:nPn2Q48Rba
Further company coverage: 4528.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
U.S. STOCKS ON THE MOVE-Macy's, American Eagle, Designer Brands
U.S. STOCKS ON THE MOVE-Copper miners, BKV, Kinetik
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)